Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease
0
Zitationen
8
Autoren
2026
Jahr
Abstract
The results of this feasibility trial provide preliminary, hypothesis-generating evidence that CDP-based second-generation AI-driven personalized Levodopa dosing regimens may be technically feasible and potentially associated with clinical improvements in PD patients. However, the open-label design, small sample size, and absence of control conditions necessitate cautious interpretation. Adequately powered, randomized, double-masked controlled trials are needed to confirm these findings and rigorously evaluate efficacy and long-term effects.
Ähnliche Arbeiten
"Why Should I Trust You?"
2016 · 14.307 Zit.
A Comprehensive Survey on Graph Neural Networks
2020 · 8.679 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.207 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.607 Zit.
Artificial intelligence in healthcare: past, present and future
2017 · 4.411 Zit.